Race Oncology Ltd. announced that Dr David Fuller has resigned as Chief Medical Officer (CMO), effective 11 November 2022, to take up the role of CMO at Aucentra Therapeutics. Dr Fuller is succeeded by Dr Ajay Duggal of Adnovate Clinical who commences on 14 November 2022 as interim CMO, pending appointment of a new full time CMO. The interim CMO will work closely with Race's executive and clinical team who have been intimately involved in all aspects of the design and implementation of Race's clinical programs. All clinical programs are expected to continue without disruption.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.405 AUD | -3.77% | -5.70% | +67.26% |
03-26 | Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6% | MT |
03-18 | Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+67.26% | 163M | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- RAC Stock
- News Race Oncology Limited
- Race Oncology Ltd Announces Management Changes